Evidence map›Paper›PMID 29456800›Full record

ArticleACS medicinal chemistry letters2018

Discovery and in Vitro Optimization of 3-Sulfamoylbenzamides as ROMK Inhibitors.

Matthew F Sammons, Sujay V Kharade, Kevin J Filipski, Markus Boehm, Aaron C Smith, Andre Shavnya, Dilinie P Fernando, Matthew S Dowling, Philip A Carpino, Neil A Castle and 5 more

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS medicinal chemistry letters, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 41% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 7 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Matthew F SammonsPfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States.
Sujay V KharadeDepartment of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States.
Kevin J FilipskiPfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States.
Markus BoehmPfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States.
Aaron C SmithPfizer Worldwide Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States.
Andre ShavnyaPfizer Worldwide Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States.
Dilinie P FernandoPfizer Worldwide Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States.
Matthew S DowlingPfizer Worldwide Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States.
Philip A CarpinoPfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States.
Neil A CastleNeusentis, Pfizer Worldwide Research & Development, Durham, North Carolina 27703, United States.
Shannon G ZellmerNeusentis, Pfizer Worldwide Research & Development, Durham, North Carolina 27703, United States.
Brett M AntonioNeusentis, Pfizer Worldwide Research & Development, Durham, North Carolina 27703, United States.
James R GossetPfizer Worldwide Research & Development, 610 Main Street, Cambridge, Massachusetts 02139, United States.
Anthony CarloPfizer Worldwide Research & Development, Eastern Point Road, Groton, Connecticut 06340, United States.
Jerod S DentonDepartment of Anesthesiology, Vanderbilt University Medical Center, Nashville, Tennessee 37232, United States.
Pfizer (United States) · USVanderbilt University Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Inhibitors of the renal outer medullary potassium channel (ROMK) show promise as novel mechanism diuretics, with potentially lower risk of diuretic-induced hypokalemia relative to current thiazide and loop diuretics. Here, we report the identification of a novel series of 3-sulfamoylbenzamide ROMK inhibitors. Starting from HTS hit

Identifiers

PMID29456800
PMCPMC5807870
OpenAlexW2784988793

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.